Novo Nordisk Us - Search News

Medicare, Wegovy and Novo Nordisk

US targets Novo Nordisk's Ozempic and Wegovy for Medicare price talks

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for Medicare price negotiations for 2027, the U.S. government said on Friday.

news.bloomberglaw · 1h

Novo’s Ozempic, Wegovy Targeted for Medicare Price Cuts (1)

The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy, the latest drugs to be targeted under legislation that’s expected save the government more than $200 billion over a decade.

CBS News on MSN · 2h

Ozempic, Wegovy on list for Medicare drug price negotiations

Medicare announced Friday that it has selected 15 drugs, including the hugely popular medications Ozempic and Wegovy, used for diabetes and weight loss, as well as some blockbuster cancer medications and other drugs,

Danish, Donald Trump and Novo Nordisk

Reuters · 23h

Novo Nordisk, other firms meet Danish PM to discuss Trump tariff threats

Danish businesses are concerned about a possible trade conflict with the United States over Greenland, a major lobby group said on Thursday after business leaders, including CEO of obesity drugmaker Novo Nordisk,

Bloomberg on MSN · 1d

Novo Nordisk CEO, Others to Discuss Trump Tariff Threats With Danish Prime Minister

The head of Ozempic maker Novo Nordisk A/S is among business executives who are meeting the Danish prime minister to discuss potential measures by the incoming Trump administration amid escalating tensions over Greenland.

Fortune on MSN · 58m

Novo Nordisk CEO attends crisis talks with Danish PM amid Donald Trump Greenland threats

Bosses from Fortune 500 Europe companies including Novo Nordisk, Lego, and Carlsberg met with the PM as Trump ups his threats over Greenland.

19hon MSN

Novo Holdings looks to double Catalent size with eye on Trump US manufacturing focus

Novo Holdings, the controlling shareholder of Novo Nordisk, hopes to double the size of its recently acquired contract ...

Finally An Attractive Entry Point Into Novo Nordisk

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...

devdiscourse19h

Novo Holdings Aims to Double Catalent's Size Amid U.S. Manufacturing Shift

Novo Holdings plans to double its newly acquired contract drugmaker, Catalent, within five years, focusing on U.S. manufacturing. The $16.5 billion acquisition is aimed at enhancing supply chains amid ...

24/7 Wall St3d

Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030

Founded a century ago, Copenhagen-based Nordisk originally made insulin. After coming to the US in 1982, it underwent several corporate changes until becoming Novo Nordisk in 1989. In addition ...

Novo Nordisk: Excellent Opportunity To Buy The Dip

Novo Nordisk's financial strength is evident through its 74% historical average ROIC and 85% gross margin. See why I rate NVO ...

9don MSN

Does Novo Nordisk A/S (NVO) Have an Attractive Valuation?

ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” fourth ...

Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence

Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a 72-week efficacy and safety trial investigating ...

Novo Nordisk: From Peak Performance To Needing A Booster Shot

I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results